Dear E, It's been a decade of remarkable advancement for the immuno-oncology field after Bristol Myers' groundbreaking Yervoy approval way back in 2011. Now, with Merck's Keytruda leading the pack, the checkpoint inhibitor class of cancer drugs is pulling down tens of billions of dollars in revenues annually. But what's next? Join us at Fierce JPM Week on January 10, 2023 at the Fairmont in San Francisco as Fierce brings together a panel of leading industry experts to dive into the future of checkpoint inhibitors. Save $100 off the current low rate! There are limited passes available at this rate until Dec 22nd. Register now before it's too late. Can’t join us in person this January? Learn more about the Virtual Only option. |
